Sarcoma

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)  
 
 
Bernadette Brennan, Laura Kirton, Perrine Marec-Berard, et al.
 
The abstract concludes: 
VDC/IE chemotherapy is superior to VIDE for both EFS and OS, with no excess toxicity. This benefit is consistent across all baseline stratification parameters. Clinical trial information: ISRCTN92192408.
—————————————————————————————————————————————————————————————————————————————
 
 
Uta Dirksen, Vivek Bhadri, Bénédicte Brichard, et al.
 
The abstract concludes: 
In patients with very high risk EwS, additional HDTreoMel was of no benefit for the entire cohort of patients. HDTreoMel may be of benefit for children age < 14. This observation is supported by comparable results from a non-randomized trial EE99 R3 (Ladenstein et al. JCO, 2010). Clinical trial information: NCT00987636.
—————————————————————————————————————————————————————————————————————————————
 
 
Martin G. McCabe, Laura Kirton, Maria Khan, et al.
 
The abstract concludes: 
The first randomised trial in RR-ES has shown that IT, used as a control arm in planned and ongoing randomised phase II studies in RR-ES, is less effective than A and B in achieving tumour shrinkage or prolonging PFS and OS. The remaining two arms are continuing to recruit patients. Clinical trial information: ISRCTN36453794.
—————————————————————————————————————————————————————————————————————————————
 
 
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
 
The abstract concludes: 
About 50% of deaths can be avoided during the first decade of follow-up after surgery with 3-year imatinib treatment as compared to 1-year treatment. Clinical trial information: NCT00116935.
 
Published simultaneously in JAMA Oncology:
—————————————————————————————————————————————————————————————————————————————
 
 
Kazuhiro Tanaka, Ryunosuke Machida, Akira Kawai, et al.
 
The abstract concludes: 
Although the toxicities were modest in GD, non-inferiority of GD to AI could not be confirmed. In the perioperative chemotherapy for high-grade STS in the extremities and trunk, AI remains the standard regimen. Clinical trial information: UMIN000013175.
—————————————————————————————————————————————————————————————————————————————
 
 
Christina Lynn Roland, Emily Zhi-Yun Keung, Alexander J. Lazar, et al.
 
The abstract concludes: 
N/RT and I/N/RT have significant clinical activity in UPS; more than expected compared to historic controls. Toxicity profiles were as expected and the majority of patients underwent resection without delay. Larger studies evaluating N/RT in UPS are warranted given the significant path response in this cohort. RECIST was not associated with path response and better markers of on-treatment clinical activity are needed. Correlative analyses that may guide combination strategies are ongoing and will be presented at the meeting. Clinical trial information: NCT03307616.
—————————————————————————————————————————————————————————————————————————————
 
 
Patricia Pautier, Anne Floquet, Christine Chevreau, et al.
 
The abstract concludes: 
The Doxo +Trab combination is an effective 1st-line therapy for pts with LMS, with promising PFS and OS results and an acceptable safety profile. Merely for comparison, the most recent results of Doxo alone in metastatic LMS, given in 1st-line setting in a phase III ANNOUNCE trial conducted during the same period, reported median PFS of 6.9 months, and median OS of 21.9 months (ASCO 2019 LBA3). Results of the LMS04 trial (NCT02997358), a randomized phase III study comparing this combination vs Doxo alone in 1st-line therapy in metastatic LMS are pending. Clinical trial information: NCT02131480.
—————————————————————————————————————————————————————————————————————————————
 
 
Tom Wei-Wu Chen, Chih-Wei Yu, Ruey-Long Hong, et al.
 
The abstract concludes: 
L + E had shown promising efficacy in advanced LMS and LPS. L at 14mg/day had a better AE profile without compromising activity. The exploratory biomarker study of LEADER is ongoing. Clinical trial information: NCT03526679.
—————————————————————————————————————————————————————————————————————————————
 
 
Ping Chi, Li-Xuan Qin, Ciara Marie Kelly, et al.
 
The abstract concludes: 
This study met its primary endpoint. BINI plus imatinib is highly effective in treatment-naive advanced GIST, with expected and manageable long-term treatment-associated toxicities. The combination strategy warrants further evaluation in direct comparison with imatinib in the frontline treatment of GIST. Clinical trial information: NCT01991379.
—————————————————————————————————————————————————————————————————————————————
 
 
DISCUSSANT
Herbert H. F. Loong, MBBS | The Chinese University of Hong Kong
 
—————————————————————————————————————————————————————————————————————————————
 
 
DISCUSSANT
Patrick Leavey, MD | Univ of Texas Southwestern Medcl Ctr
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session